This case is the first report to our knowledge to have described the clinical application of an HA330-II perfusion column in children suffering from HLH. In summary, for EBV-associated HLH, HA330-II column-mediated hemoadsorption can safely reduce the levels of inflammatory cytokines, serving as a beneficial and essential supplement to chemotherapy. However, as this is a report of outcomes for a single patient, large-scale trials will be necessary to investigate the clinical indications for such hemoadsorption treatment.